Regenxbio (RGNX) Return on Sales (2014 - 2025)

Regenxbio's Return on Sales history runs 12 years deep, the most recent figure standing at 0.03% for Q4 2025.

• On a quarterly basis, Return on Sales rose 6.0% year-over-year to 0.03% in Q4 2025; TTM through Dec 2025 was 0.0%, a 3.0% increase from a year earlier, with the FY2025 full-year figure at 0.03%, down 1.0% from the prior year.
• Return on Sales improved to 0.03% in Q4 2025 per RGNX's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.09% in Q4 2022 and bottomed at 0.05% in Q1 2024.
• The 5-year median for Return on Sales is 0.03% (2021), against an average of 0.02%.
• Across the five-year window, Return on Sales gained 8 bps in 2022 and declined 12 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2021, then soared by 1108 bps to 0.09% in 2022, then plunged by 132 bps to 0.03% in 2023, then decreased by 11 bps to 0.03% in 2024, then soared by 205 bps to 0.03% in 2025.
• Per Business Quant, the three latest RGNX Return on Sales figures stand at 0.03% (Q4 2025), 0.02% (Q3 2025), and 0.03% (Q2 2025).